Microscopic disease at second-look laparotomy in advanced ovarian cancer

Copeland, Laurel; Gershenson, D. M.; Jt, Wharton; Edwards, Cynthia; Rutledge, Felix N.

doi:10.1016/0090-8258(83)90137-3

Cited by 17 publications

(22 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This will reveal a 55% rate of residual disease and a 45% negative findings after the pathological evaluations [3][4][5][6][7][8][9][10][11][12]. We found a 52.7% rate of negative SLL and this was in accordance with some previous reports [8,12,16,17,26].…”

Section: Discussionsupporting

confidence: 95%

“…Second look laparatomy (SLL) is a question of matter for these subset of patients since it will reveal 33-70% (mean 50%) residual disease in these patients. Of these patients; about 34% will have gross residual disease and so may be the subject of a secondary cytoreductive surgery during the procedure [3][4][5][6][7][8][9][10][11][12]. The remaining 45% of the patients with no pathologically proven disease (negative SLL) is the subject focused in this report.…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Predictors and outcomes of recurrent disease after a negative second look laparotomy

Ayhan

Gültekin

Dursun

et al. 2007

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 95%

Section: Introductionmentioning

confidence: 98%

Predictors and outcomes of recurrent disease after a negative second look laparotomy

Ayhan

Gültekin

Dursun

et al. 2007

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…The results of this study show that patients with microscopic remnants at second look have a similar survival to that of patients who arc histopathologically free of disease. This finding is consistent with data reported by others [13][14][15] However, a shorter follow up and a difference in the duration of treatment (pa tients with PMiR received 5 additional cycles of therapy) could have accounted for the absence of a significant difference in survival in our series, mainly because groups were not comparable.…”

Section: Discussionsupporting

confidence: 81%

Chemotherapy (CAP) for the Treatment of Advanced Ovarian Cancer and Second-Effort Surgery in the Second Look

Ojeda-González¹,

Álvarez-López²,

Alonso-Muñoz³

et al. 1991

Oncology

View full text Add to dashboard Cite

Seventy-two patients with advanced ovarian cancer received CAP chemotherapy followed by laparotomy and ‘second-effort’ surgery. The overall response to CAP therapy was 80%. A complete pathological response (CPR) was obtained in 16 patients and partial microscopic (PMiR) and macroscopic responses in 7 and 33 cases, respectively. The actuarial survival for the entire group was 36% at 50 months with a median survival of 34 months. No significant differences in survival between the CPR and PMiR groups were found. Radical second-effort surgery showed a somewhat beneficial effect. The tumor size before chemotherapy ( < 5 cm) and FIGO stage III had a significantly favorable effect on response rate and survival.

show abstract

“…No salvage chemotherapy regimen has been shown to be effective in improving survival in this group of patients. However, several studies have shown that salvage or consolidation chemotherapy can confer a definite benefit in patients with microscopic disease detected during second-look procedures, with 5-year survival rates as high as 70% (35,36). Given that patients with falsenegative second-look procedures are likely to harbor microscopic disease, the prospects of identifying such patients, followed by administration of additional chemotherapy, may confer a better survival.…”

Section: Discussionmentioning

confidence: 99%

Detection of Residual Subclinical Ovarian Carcinoma after Completion of Adjuvant Chemotherapy

Nouriani

Bahador

Berek

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose:We sought to test the hypothesis that the presence of telomerase activity in peritoneal washings of patients treated for ovarian carcinoma is a sensitive and specific indicator of the presence of residual disease. We hypothesized that this test, if added to second-look procedure protocols, could help determine whether residual disease is present or not in patients who have completed their adjuvant chemotherapy for ovarian carcinoma.Experimental Design: Peritoneal washings were obtained from 100 consecutive patients undergoing a secondlook procedure after treatment for ovarian carcinoma (cases) and from 100 patients undergoing surgery for benign gynecological conditions (controls). The washings were assayed for telomerase activity using the telomerase repeat amplification protocol. The results were compared to the histological and cytological findings.Results: Among our 100 cases, 82 (82%) had either positive second-look procedures or expressed telomerase in their peritoneal washings. Fifty-three (53%) had positive second-look procedures, whereas 66 (66%) tested positive for telomerase. Twenty-nine of the 47 patients (62%) with negative second-look procedures tested positive for telomerase. Of the 53 patients with positive second-look procedures, 37 (70%) tested positive for telomerase. None of the 100 controls (0%) expressed telomerase in their peritoneal washings.Conclusions: Telomerase activity in peritoneal washings of patients treated for ovarian carcinoma and undergoing a second-look procedure may provide a means of increasing the sensitivity of such procedures for the detection of residual disease while maintaining a high level of specificity.

show abstract

Microscopic disease at second-look laparotomy in advanced ovarian cancer

Cited by 17 publications

References 0 publications

Predictors and outcomes of recurrent disease after a negative second look laparotomy

Predictors and outcomes of recurrent disease after a negative second look laparotomy

Chemotherapy (CAP) for the Treatment of Advanced Ovarian Cancer and Second-Effort Surgery in the Second Look

Detection of Residual Subclinical Ovarian Carcinoma after Completion of Adjuvant Chemotherapy

Contact Info

Product

Resources

About